28th May 2009 16:15
|
Press Release |
28 May 2009 |
LiDCO Group Plc
("LiDCO" or the "Company")
Grant of Share Options
The Board of LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that on 27 May 2009, in accordance with the Company's Employee Share Option Schemes, the following options were granted to subscribe for new ordinary shares in the Company to three Directors and to the Company Secretary as follows:
|
Director |
Number |
Exercise Price |
Exercise Period |
Total Number of options held |
|
Terry O'Brien |
150,000 |
12.67p |
2012 - 2019 |
1,177,395 |
|
John Barry |
150,000 |
12.67p |
2012 - 2019 |
3,237,017 |
|
Paul Clifford |
75,000 |
12.67p |
2012 - 2019 |
141,000 |
|
Company Secretary |
||||
|
John Rowland |
25,000 |
12.67p |
2012 - 2019 |
90,000 |
In addition, options over a further 809,000 new ordinary shares have been granted to employees of the Company on the same terms.
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 www.lidco.com |
|
FinnCap |
|
|
Geoff Nash / Marc Young / Stephen Norcross |
+44 (0)20 7600 1658 www.finncap.com |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Stephanie Cuthbert / Simone Alves |
+44 (0)20 7398 7728 www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's manufacturing facility is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery.
* Early and rapid warning of change
* Clear indication of therapeutic route: fluid or drug
* Quantification of hemodynamic response, particularly stroke volume
* Permits more effective delivery of fluids - the right amount at the right time
*Advanced hemodynamic care has been shown to:
- Contribute to reduced morbidity and complications
- Reduce length of stay
- Reduce overall cost of care
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors.
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase
LiDCO Distribution Network:
The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.
Related Shares:
LID.L